Martin-Luther-Universität Halle-Wittenberg, Halle(Saale), Germany.
Oncology. 2012;82(4):218-27. doi: 10.1159/000336892. Epub 2012 Apr 12.
The prognosis for patients with triple-negative breast cancer (TNBC) is poor and treatment options are limited. Bevacizumab improves the efficacy of standard first-line therapy in locally recurrent/metastatic breast cancer (LR/mBC). The benefit of bevacizumab seen in patients with TNBC appears similar to that observed in the overall population. We conducted an exploratory analysis of patients with TNBC treated in the single-arm routine oncology practice ATHENA study.
Patients with previously untreated LR/mBC received standard first-line chemotherapy combined with bevacizumab (10 mg/kg every 2 weeks or 15 mg/kg every 3 weeks, until progression, unacceptable toxicity, or patient/physician decision).
Of 2,264 patients treated in ATHENA, 585 (26%) had TNBC. Most patients received single-agent taxane with bevacizumab. In the TNBC subgroup, the overall response rate was 49%, including complete responses in 10%; only 16% had primary resistant disease. Median time to progression was 7.2 months (95% CI 6.6-7.8) and median overall survival was 18.3 months (95% CI 16.4-19.7). The 1-year overall survival rate was 60%. The safety profile in TNBC was consistent with results in the overall population.
This exploratory subgroup analysis suggests that first-line chemotherapy in combination with bevacizumab is an active regimen in patients with metastatic TNBC.
三阴性乳腺癌（TNBC）患者的预后较差，治疗选择有限。贝伐珠单抗可提高局部复发性/转移性乳腺癌（LR/mBC）标准一线治疗的疗效。在 TNBC 患者中观察到的贝伐珠单抗的获益与在总体人群中观察到的获益相似。我们对 ATHENA 单臂常规肿瘤学实践研究中接受治疗的 TNBC 患者进行了探索性分析。
未经治疗的 LR/mBC 患者接受标准一线化疗联合贝伐珠单抗（10mg/kg，每 2 周 1 次或 15mg/kg，每 3 周 1 次，直至疾病进展、不可接受的毒性或患者/医生决定）。
在 ATHENA 中接受治疗的 2264 例患者中，有 585 例（26%）患有 TNBC。大多数患者接受了单药紫杉烷联合贝伐珠单抗治疗。在 TNBC 亚组中，总体缓解率为 49%，包括 10%的完全缓解；仅有 16%的患者存在原发性耐药疾病。无进展生存期为 7.2 个月（95%CI 6.6-7.8），总生存期为 18.3 个月（95%CI 16.4-19.7）。1 年总生存率为 60%。TNBC 中的安全性特征与总体人群中的结果一致。
这项探索性亚组分析表明，一线化疗联合贝伐珠单抗是转移性 TNBC 患者的一种有效治疗方案。
